Treatment options for paediatric diabetes

Bibliography

• Craig ME, Hattersley A, Donaghue KC. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes 2009;10:3-12
   PubMed Web of Science ®Google Scholar
• Thunander M, Petterson C, Jonzon K, Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden. Diabetes Res Clin Pract 2008;82:247-55
   PubMed Web of Science ®Google Scholar
• Soltesz G. Diabetes in the young: a paediatric and epidemiological perspective. Diabetologia 2003;46:447-54
   PubMed Web of Science ®Google Scholar
• Patterson CC, Dahlquist GG, Gyurus E, Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009;373:2027-33
   PubMed Web of Science ®Google Scholar
• Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008;371:1777-82
   PubMed Web of Science ®Google Scholar
• Wilkin TJ. The great weight gain experiment, accelerators, and their implications for autoantibodies in diabetes. Arch Dis Child 2006;91:456-8
   Google Scholar
• Rosenbloom AL, Silverstein JH, Amemiya S, ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Type 2 diabetes in children and adolescents. Pediatr Diabetes 2009;10:17-32
   PubMedGoogle Scholar
• Danne T, Becker D. Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes. Acta Paediatr 2007;96:1560-70
   Google Scholar
• Donaghue KC, Chiarelli F, Trotta D, ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Microvascular and macrovascular complications associated with diabetes in children and adolescents. Pediatr Diabetes 2009;10:195-203
   Google Scholar
• Parentie DC, Lim A, Wu J, Effect of prior hypoglycemia and hyperglicemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes 2008;9:87-95
   Google Scholar
• Danne T, Mortensen HB, Hougaard P, Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group. Diabetes Care 2001;24:1342-47
   PubMedGoogle Scholar
• Marcovecchio ML, Tossavainen PH, Dunger DB. Prevention and treatment of microvascular disease in childhood type 1 diabetes. Br Med Bull 2010. [Epub ahead of print]
   Google Scholar
• White NH, Cleary PA, Dahms W, Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001;139:804-12
   PubMed Web of Science ®Google Scholar
• Shalitin S, Phillip M. The role of new technologies in treating children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2007;8:72-9
   Google Scholar
• Ioacara S, Lichiardopol R, Ionescu-Tirgoviste C, Improvements in life expectancy in type 1 diabetes patients in the last six decades. Diabetes Res Clin Pract 2009;86:146-51
   Google Scholar
• Bangstad H-J, Danne T, Deeb LC, ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009:10:82-99
   PubMedGoogle Scholar
• Sheldon B, Russel-Jones D, Wright J. Insulin analogues: an example of applied medical science. Diabetes Obes Metab 2009;11:5-19
   PubMed Web of Science ®Google Scholar
• Simpson D, McCormack PL, Keating GM, Lyseng-Williamson KA. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs 2007;67:407-34
   PubMed Web of Science ®Google Scholar
• Ford-Adams ME, Murphy NP, Moore EJ, Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003;20:656-60
   PubMed Web of Science ®Google Scholar
• Plank J, Wutte A, Brunner G, A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-7
   PubMed Web of Science ®Google Scholar
• Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet 2001;40:641-59
   PubMed Web of Science ®Google Scholar
• Helms KL, Kelley KW. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application. Ann Pharmacother 2009;43:658-68
   PubMed Web of Science ®Google Scholar
• Danne T, Becker RH, Heise T, Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005;28:2100-5
   PubMed Web of Science ®Google Scholar
• Danne T, Aman J, Schober E, ; ANA 1200 Study Group. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:2359-64
   PubMed Web of Science ®Google Scholar
• Swan KL, Dziura JD, Steil GM, Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care 2009;32:240-4
   PubMed Web of Science ®Google Scholar
• Siebenhofer A, Plank J, Berghold A, Short acting insulin analogs versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006:CD003287
   Google Scholar
• Danne T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther 2007;29:145-52
   PubMedGoogle Scholar
• Danne T, Rastam J, Odendahl R, Parental preference of prandial insulin aspart compared to preprandial human insulin in a basal-bolus scheme with NPH insulin in a twelve week crossover-study of preschool children with type 1 diabetes. Pediatr Diabetes 2007;8:278-85
   PubMed Web of Science ®Google Scholar
• Hassan K, Rodriguez LM, Johnson SE, A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008;121:466-72
   Google Scholar
• Adhikari S, Adams-Huet B, Wang YC, Institution of basal-bolus therapy at diagnosis for children with type 1 diabetes mellitus. Pediatrics 2009;123:673-8
   Web of Science ®Google Scholar
• Lepore M, Pampanelli S, Fanelli C, Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49(12):2142-8
   Google Scholar
• Dixon B, Peter Chase H, Burdick J, Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005;6:150-4
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talback M, Insulin glargine use and short-term incidence of malignancies- a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-54
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44
   PubMed Web of Science ®Google Scholar
• Currie, Poole CD, Gale EAM. The influence of glucose-lowering therapies risk in type 2 diabetes. Diabetologia 2009;52:1766-77
   PubMed Web of Science ®Google Scholar
• SDRN Epidemiology group. Use of insulin glargine and cancer incidence in Scotland: a study from Scottish Diabetes research network Epidemiology group. Diabetologia 2009;52:1755-65
   Google Scholar
• Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-506
   PubMed Web of Science ®Google Scholar
• Kurtzhals P. Pharmacology of insulin detemir. Endocrinol Metab Clin North Am 2007;36:14-20
   PubMed Web of Science ®Google Scholar
• Danne T, Datz N, Endahl L, Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008;9:554-60
   PubMedGoogle Scholar
• Chase HP, Dixon B, Pearson J, Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003;143:737-40
   PubMed Web of Science ®Google Scholar
• Robertson KJ, Schoenle E, Gucev Z, Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007;24:27-34
   PubMed Web of Science ®Google Scholar
• Danne T, Lupke K, Walte K, Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-92
   PubMed Web of Science ®Google Scholar
• Becker RH, Frick AD, Nosek L, Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care 2007;30:2506-7
   PubMed Web of Science ®Google Scholar
• Iafusco D. Insulin therapy regimens in paediatric age. Acta Biomed 2005;76:39-43
   Google Scholar
• Nathan DM, Cleary PA, Backlund JY, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
   PubMed Web of Science ®Google Scholar
• Steck AK, Klingensmith GJ, Fiallo-Scharer R. Recent advances in insulin treatment of children. Pediatr Diabetes 2007;8:49-56
   Google Scholar
• Tan CY, Wilson DM, Buckingham B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2004;5:80-6
   PubMed Web of Science ®Google Scholar
• Rewers M, Pihoker C, Donaghue K, ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2009;10:71-81
   Google Scholar
• Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-toinsulin ratio. Endocr Pract 2008;14:1095-101
   PubMedGoogle Scholar
• Beck JK, Lewis TV, Logan KJ, Intensive vs. conventional insulin management initiated at diagnosis in children with diabetes: should payer source influence the choice of therapy? Pediatr Diabetes 2009;10:368-73
   Google Scholar
• Kapellen TM, Heidtmann B, Bachmann J, Indications for insulin pump therapy in different age groups: an analysis of 1,567 children and adolescents. Diabet Med 2007;24:836-42
   PubMed Web of Science ®Google Scholar
• Phillip M, Battelino T, Rodriguez H, Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007;30:1653-62
   PubMed Web of Science ®Google Scholar
• Shalitin S, Phillip M. The use of insulin pump therapy in the pediatric age group. Horm Res 2008;70:14-21
   Google Scholar
• Colquitt J, Royle P, Waugh N. Are analog insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003;20:863-6
   Google Scholar
• Kerr D, Morton J, Whately-Smith C, Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Tech 2008;2:450-5
   PubMedGoogle Scholar
• Weinzimer SA, Ternar C, Howaed C, The Insulin Aspart Paediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008;31:210-15
   PubMed Web of Science ®Google Scholar
• Deiss D, Hartmann R, Hoeffe J, Kordonouri O. Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy. Pediatr Diabetes 2004;5:117-21
   Google Scholar
• Lepore G, Dodesini AR, Nosari I, Trevisan R. Effect of continuous subcutaneous insulin infusion vs. multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study. Diabetes Nutr Metab 2004;17:84-9
   PubMedGoogle Scholar
• Schiaffini R, Patera PI, Bizzarri C, Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin. J Endocrinol Invest 2007;30:572-7
   Google Scholar
• Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta analysis of randomised controlled trials. BMJ 2002;324:1-6
   PubMed Web of Science ®Google Scholar
• Weinzimer SA, Ahern JH, Doyle EA, Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004;114:1601-5
   PubMed Web of Science ®Google Scholar
• Hanas R, Lundqvist K, Windell L. Blood glucose and beta-hydroxybutyrate responses when the insulin pump is stopped in children and adolescents. Pediatr Diabetes 2006;7:35
   Google Scholar
• Robertson K, Schonle E, Gucev Z, Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycaemia. Diabet Med 2007;24:27-34
   PubMed Web of Science ®Google Scholar
• Berghaeuser MA, Kapellen T, Heidtmann B, Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes 2008;9:590-5
   PubMed Web of Science ®Google Scholar
• McMahon SK, Airey FL, Marangou DA, Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. Diabet Med 2005;22:92-6
   PubMed Web of Science ®Google Scholar
• Wood JR, Moreland EC, Volkening EK, Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care 2006;29:2355-60
   PubMed Web of Science ®Google Scholar
• Pohar SL. Subcutaneous open-loop insulin delivery for type 1 diabetes: paradigm real-time system. Issues Emerg Health Technol 2007;105:1-6
   Google Scholar
• Cohen N, Minshall ME, Sharon-Nash L, Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007;25:881-97
   PubMed Web of Science ®Google Scholar
• Nuboer R, Bruining J. Cost-effectiveness of continuous subcutaneous insulin infusion (CSII) in children: illusion or delusion? Pediatr Diabetes 2006;7:39-44
   Google Scholar
• Yamaoka T. Gene therapy for diabetes mellitus. Curr Mol Med 2001;1:325-37
   PubMedGoogle Scholar
• Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care 2009;32:1563-9
   Web of Science ®Google Scholar
• Robertson PR. Islet transplantation as a treatment for diabetes-A work in progress. N Engl J Med 2004;350:694-705
   PubMed Web of Science ®Google Scholar
• Shapiro AMJ, Lakey JRT, Ryan EA, Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-8
   PubMed Web of Science ®Google Scholar
• Vantyghem M-C, Kerr-Conte J, Arnalsteen L, Primary graft function, metabolic control, and graft survival after islet transplantation. Diabetes Care 2009;32:1473-8
   PubMed Web of Science ®Google Scholar
• Bellin MD, Kandaswamy R, Parkey J. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant 2008;8:2463-70
   PubMedGoogle Scholar
• Bottino R, Balamurugan AN, Giannoukakis N, Trucco M. Islet/pancreas transplantation: challenges for pediatrics. Pediatr Diabetes 2002;3:210-23
   Google Scholar
• Fiorina P, Folli F, Bertuzzi F, Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 2003;26:1129-36
   PubMed Web of Science ®Google Scholar
• Harlan DM, Kenyon NS, Korsgren O, Roep BO. Immunology of Diabetes Society. Current advances and travails in islet transplantation. Diabetes 2009;58:2175-84
   PubMed Web of Science ®Google Scholar
• Jun HS, Yoon JW. Approaches for the cure of type 1 diabetes by cellular and gene therapy. Curr Gene Ther 2005;5:249-62
   PubMed Web of Science ®Google Scholar
• Lee DD, Grossman E, Chong AS. Cellular therapies for type I diabetes. Horm Metab Res 2008;40:147-54
   Google Scholar
• TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes 2007;8:117-37
   Google Scholar
• Schmid S, Buuck D, Knopff A, BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with Type 1 diabetes by delaying exposure to gluten. Diabetologia 2004;47:1130-1
   PubMedGoogle Scholar
• Chase HP, Lescheck E, Rafkin-Mervis L, Nutritional intervention to prevent (NIP) type 1 diabetes a pilot study. ICAN 2009;1:98-107
   Google Scholar
• Zipitis CS, Akobeng AK. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008;93:512-7
   PubMed Web of Science ®Google Scholar
• Achenbach P, Barker J, Bonifacio E. Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 2008;8:87-93
   PubMedGoogle Scholar
• Gale EA, Bingley PJ, Emmett CL, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004;363:925-31
   PubMed Web of Science ®Google Scholar
• Nanto-Salonen K, Kupila A, Simell S, Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372:1746-55
   PubMed Web of Science ®Google Scholar
• Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes. Diabetes Care 2009;10:1769-82
   Google Scholar
• Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 2010;32:488-99
   PubMed Web of Science ®Google Scholar
• Schloot NC, Meierhoff G, Lengyel C, Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007;23:276-85
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev 2009;25:307-15
   PubMed Web of Science ®Google Scholar
• Yoon JW, Yoon CS, Lim HW, Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999;284:1183-7
   PubMed Web of Science ®Google Scholar
• Agardh CD, Cilio CM, Lethagen A, Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005;19:238-46
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hedman M, GAD65 treatment and residual insulin secretion in recent onset type 1 diabetes. N Engl J Med 2008;30:1909-20
   Web of Science ®Google Scholar
• Ludvigsson J. Linkoping Diabetes Immune Intervention Study Group. The role of immunomodulation therapy in autoimmune diabetes. J Diabetes Sci Technol 2009;3:320-30
   Google Scholar
• Jacobson-Dickman E, Levitsky L. Oral agents in managing diabetes mellitus in children and adolescents. Pediatr Clin North Am 2005;52:1689-703
   Google Scholar
• Jones KL, Arslanian S, Peterokova VA, Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94
   PubMed Web of Science ®Google Scholar
• Shield JPH, Lynn R, Wan KC, Management and 1 year outcome for UK children with type 2 diabetes. Arch Dis Child 2009;94:206-9
   Google Scholar
• Gottschalk M, Danne T, Vlajnic A, Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care 2007;30:790-4
   PubMed Web of Science ®Google Scholar
• Zeitler P, Epstein L, Grey M, Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8:74-87
   PubMed Web of Science ®Google Scholar
• Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag 2009;5:141-51
   PubMedGoogle Scholar